These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22520768)

  • 1. Buprenorphine versus methadone use in opiate detoxification, are there other factors that should be considered?
    Bhupal HK
    Br J Gen Pract; 2012 Feb; 62(595):68-9. PubMed ID: 22520768
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.
    Wright NM; Sheard L; Adams CE; Rushforth BJ; Harrison W; Bound N; Hart R; Tompkins CN
    Br J Gen Pract; 2011 Dec; 61(593):e772-80. PubMed ID: 22137413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer from high dose methadone to buprenorphine/naloxone.
    Wallace M
    Aust Nurs J; 2011 Jul; 19(1):42-3. PubMed ID: 21853690
    [No Abstract]   [Full Text] [Related]  

  • 4. Promise of extended-release naltrexone is a red herring.
    Bart G
    Lancet; 2011 Aug; 378(9792):663; author reply 663-4. PubMed ID: 21856474
    [No Abstract]   [Full Text] [Related]  

  • 5. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
    J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid dependence.
    Praveen KT; Law F; O'Shea J; Melichar J
    Am Fam Physician; 2012 Sep; 86(6):565-6. PubMed ID: 23062049
    [No Abstract]   [Full Text] [Related]  

  • 7. Commercial factors override science in combination addiction drug trial.
    Byrne A
    Clin Pharmacol Ther; 2011 Nov; 90(5):649; author reply 650. PubMed ID: 21956617
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacology Update: Probuphine: The Long-Acting Buprenorphine Implant.
    Lorman WJ
    J Addict Nurs; 2019; 30(2):123-124. PubMed ID: 31162216
    [No Abstract]   [Full Text] [Related]  

  • 9. [Evolution and update of detoxification techniques for opiate addicts].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2000 Oct; 20(4):175-7. PubMed ID: 11215403
    [No Abstract]   [Full Text] [Related]  

  • 10. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
    Kelty E; Hulse G
    Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
    Terasaki D; Smith C; Calcaterra SL
    Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating prescription opioid dependence.
    Ruetsch C
    JAMA; 2014 Sep; 312(11):1145-6. PubMed ID: 25226480
    [No Abstract]   [Full Text] [Related]  

  • 13. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
    Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription opioid dependence: the clinical challenge.
    Newman RG
    JAMA Psychiatry; 2014 Mar; 71(3):338. PubMed ID: 24599244
    [No Abstract]   [Full Text] [Related]  

  • 16. Medications for Opioid Use Disorder: A Guide for Physicians.
    Azhar N; Chockalingam R; Azhar A
    Mo Med; 2020; 117(1):59-64. PubMed ID: 32158052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Substitutions therapy of opiate addiction in Denmark].
    Ishøy T; Iversen C
    Ugeskr Laeger; 2003 Sep; 165(38):3620-3. PubMed ID: 14556394
    [No Abstract]   [Full Text] [Related]  

  • 18. Buprenorphine for opiate dependence: clinic based therapy in Israel.
    Goren L; Carmel Z; Marchevsky S
    Isr J Psychiatry Relat Sci; 2014; 51(4):281-4. PubMed ID: 25841225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
    Soyka M
    Pharmacopsychiatry; 2021 Jan; 54(1):18-22. PubMed ID: 33212514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of buprenorphine precipitated withdrawal: a case report.
    Jutras-Aswad D; Widlitz M; Scimeca MM
    Am J Addict; 2012; 21(5):492-3. PubMed ID: 22882402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.